Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood (2023) 141 (6): 579–591.

https://doi.org/10.1182/blood.2022016782

Published: 2023

Includes: Supplemental data

Journal Articles

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi-Ankrah, Arun Kumar, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar

Blood (2021) 138 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2021-147838

Published: 2021

Journal Articles

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Bruno Paiva, PhD, Irene Manrique, PhD, Nicola Giuliani, Michele Cavo, Christine Rojas, MD, Weijun Fu, MD PhD, María-Victoria Mateos, MD PhD, Meletios A Dimopoulos, Alexander Vorog, MD, Cong Li, PhD, Bingxia Wang, PhD, Richard J Labotka, MD, Ajeeta B Dash, PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-136105

Published: 2020

Journal Articles

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Wassilis S.C. Bruins, MDMSc, Wenrou Zheng, MSc, Jack P. Higgins, PhD, Erin K. Willert, PhD, John Newcomb, PhD, Ajeeta B Dash, PhD, Niels W.C.J. Van De Donk, MD PhD, Sonja Zweegman, MDPhD, Tuna Mutis, MD PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136928

Published: 2020

Journal Articles

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Soo Park, MD, Brian M Reilly, BS, Timothy Luger, Dan Zhao, Robert J. Fram, MD, Ajeeta B Dash, PhD, Rafael Bejar, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-134484

Published: 2020

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Bin Li, PhD, Kaili Ren, PhD, Lei Shen, PhD, Peijie Hou, PhD, Zhenqiang Su, PhD, Alessandra Di Bacco, PhD, Jin-Liern Hong, PhD, Aaron Galaznik, PhD, Ajeeta B Dash, PhD, Victoria Crossland, PhD, Paul Dolin, DPhil, Sandor Szalma, PhD

Blood (2018) 132 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2018-99-115017

Published: 2018

Journal Articles

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Ajeeta B Dash, PhD, Jacob Zhang, PhD, Lei Shen, PhD, Bin Li, PhD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Hervé Avet-Loiseau, MDPhD, Nizar Bahlis, MD, Philippe Moreau, Paul Richardson, Alessandra Di Bacco, PhD

Blood (2018) 132 (Supplement 1): 473.

https://doi.org/10.1182/blood-2018-99-114614

Published: 2018

Journal Articles

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Ronan T. Swords, Steven Coutre, Michael B. Maris, Joshua F. Zeidner, James M. Foran, Jose Cruz, Harry P. Erba, Jesus G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Iwona Pawlikowska-Dobler, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Douglas V. Faller, Michael R. Savona

Blood (2018) 131 (13): 1415–1424.

https://doi.org/10.1182/blood-2017-09-805895

Published: 2018

Includes: Supplemental data

Journal Articles

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Ronan T Swords, MD PhD FRCPI, FRCPath, Steven Coutre, MD, Michael B. Maris, MD, Joshua F. Zeidner, MD, James M. Foran, MD, Jose C. Cruz, MD, Harry P. Erba, MD PhD, Jesus G. Berdeja, MD, Wayne Tam, MD PhD, Saran Vardhanabhuti, PhD, Iwona Dobler, PhD, Hélène M. Faessel, PhD, Ajeeta B. Dash, PhD, Farhad Sedarati, PhD, Bruce J. Dezube, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 98.

https://doi.org/10.1182/blood.V128.22.98.98

Published: 2016

Journal Articles

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

Ronan T Swords, MD PhD FRCPI, FRCPath, Michael R Savona, MD, Michael B Maris, MD, Harry P Erba, MD PhD, Jesus G. Berdeja, MD, James M. Foran, MD, Zhaowei Hua, PhD, Hélène M Faessel, PharmD, PhD, Ajeeta B Dash, PhD, Farhad Sedarati, PhD, Bruce J Dezube, MD, Bruno C Medeiros, MD

Blood (2014) 124 (21): 2313.

https://doi.org/10.1182/blood.V124.21.2313.2313

Published: 2014

NARROW

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML)

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only